ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > SELL YOUR SHARES FOR TAX LOSS!!

<< Previous

Bullboard Posts

Next >>

Comment by retiredcopon Dec 06, 2020 11:25pm

167 Views

Post# 32047495

RE:SELL YOUR SHARES FOR TAX LOSS!!

So Facemask .. what can we clasiify you as right now .. I seller or a buyer .. sure hard to figure you out ... and I have 700K shares in my TFSA so you can probabaly figure out that I am not going to do any tax selling... you migh be surprised if you polled the audience here ..how many of us have our shares in a TFSA . Took advantage of the stock whenit dipped to 1.5 - 2 cents a few years ago.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market